邮件订阅 RSS

留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

晚期肾癌：治疗进展及展望

盛锡楠,  郭军

downloadPDF
文章导航 > 协和医学杂志  > 2019 >  10(2): 148-151
盛锡楠, 郭军. 晚期肾癌：治疗进展及展望[J]. 协和医学杂志, 2019, 10(2): 148-151. doi: 10.3969/j.issn.1674-9081.2019.02.012
引用本文: 盛锡楠, 郭军. 晚期肾癌：治疗进展及展望[J]. 协和医学杂志, 2019, 10(2): 148-151. doi: 10.3969/j.issn.1674-9081.2019.02.012
shu
Xi-nan SHENG, Jun GUO. Current Status and Prospects of the Treatment of Advanced Renal Carcinoma[J]. Medical Journal of Peking Union Medical College Hospital, 2019, 10(2): 148-151. doi: 10.3969/j.issn.1674-9081.2019.02.012
Citation: Xi-nan SHENG, Jun GUO. Current Status and Prospects of the Treatment of Advanced Renal Carcinoma[J]. Medical Journal of Peking Union Medical College Hospital, 2019, 10(2): 148-151. doi: 10.3969/j.issn.1674-9081.2019.02.012
shu

晚期肾癌：治疗进展及展望

doi: 10.3969/j.issn.1674-9081.2019.02.012

  • 北京大学肿瘤医院暨北京市肿瘤防治研究所肾癌黑色素瘤内科 恶性肿瘤发病机制及转化研究教育部重点实验室，北京 100142

基金项目: 

北京市医管局杨帆计划 ZYLX201603

北京市科学技术委员会首都临床特色应用研究 Z161100000516062

详细信息
    通讯作者:

    郭军电话：010-88196348，E-mail：guoj307@126.com

  • 中图分类号: R737.11; R-1

Current Status and Prospects of the Treatment of Advanced Renal Carcinoma

  • Key Laboratory of Carcinogenesis and Translational, Research Ministry of Education, Department of Renal Cancer and Melanoma, Peking University Cancer Hospital & Institute, Beijing 100142, China

More Information
    Corresponding author: GUO Jun Tel：010-88196348，E-mail：guoj307@126.com

    摘要
  • 摘要: 近10年来，靶向治疗在晚期肾癌治疗领域取得了快速发展，美国食品药品监督管理局先后批准了9项靶向药物用于治疗晚期肾癌，2015年底免疫检查点抑制剂用于晚期肾癌的二线治疗在临床研究中取得突破性进展，并且获得批准用于临床治疗。免疫或免疫与靶向联合治疗逐渐成为临床研究热点，本文对晚期肾癌的靶向与免疫治疗进展进行综述，并对其治疗前景进行展望。
    Abstract: In the past decade, the emergence of targeted therapy has provided an exciting option for the treatment of renal cell carcinoma. There were 9 targeting agents approved for the treatment of unresectable or metastatic renal carcinoma by the American Food and Drug Administration(FDA). The promise of renal carcinoma immunotherapy was officially validated in December 2015 when the FDA approved Nivoliumab for the treatment of metastatic renal carcinoma. There are an increasing number of clinical trials on immune checkpoint inhibitors alone or combined with targeting agents that are now being identified and used for renal carcinoma immunotherapy. In this review, we present a brief overview of current treatments and discuss major clinical trials and data on renal carcinoma.
    利益冲突  无
    • HTML全文
    • 参考文献(19)
  • [1] Hsieh JJ, Purdue MP, Signoretti S, et al. Renal cell carcinoma[J]. Nat Rev Dis Primers, 2017, 3:17009.
    [2] Kumar R, Kapoor A. Current management of metastatic renal cell carcinoma: evolving new therapies[J]. Curr Opin Support Palliat Care, 2017, 11:231-237. doi:  10.1097/SPC.0000000000000277
    [3] Bedke J, Gauler T, Grünwald V, et al. Systemic therapy in metastatic renal cell carcinoma[J]. World J Urol, 2017, 35:179-188. doi:  10.1007/s00345-016-1868-5
    [4] Choueiri TK, Escudier B, Powles T, et al. Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma[J]. N Engl J Med, 2015, 373:1814-1823. doi:  10.1056/NEJMoa1510016
    [5] Choueiri TK, Escudier B, Powles T, et al. Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial[J]. Lancet Oncol, 2016, 17:917-927. doi:  10.1016/S1470-2045(16)30107-3
    [6] Choueiri TK, Halabi S, Sanford BL, et al. Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial[J]. J Clin Oncol, 2017, 35:591-597. https://pubmed.ncbi.nlm.nih.gov/?term=28199818
    [7] Hammers HJ, Plimack ER, Infante JR, et al. Safety and Efficacy of Nivolumab in Combination with Ipilimumab in Metastatic Renal Cell Carcinoma: The Check Mate 016 Study[J]. J Clin Oncol, 2017, 35:3851-3858. doi:  10.1200/JCO.2016.72.1985
    [8] Motzer RJ, Tannir NM, McDermott DF, et al. Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma[J]. N Engl J Med, 2018, 378: 1277-1290. doi:  10.1056/NEJMoa1712126
    [9] McDermott DF, Atkins MB, Motzer RJ, et al. Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma[J]. Nat Med, 2018, 24:749-757. doi:  10.1038/s41591-018-0053-3
    [10] Atkins MB, McDermott DF, Powles T, et al. IMmotion150: A phase Ⅱ study in untreated metastatic renal cell carcinoma patients of atezolizumab and bevacizumab vs and following atezolizumab or sunitinib[C]. J Clin Oncol, 2017, 35: abstract 4505.
    [11] Atkins MB, Plimack ER, Puzanov I, et al. Axitinib in combination with pembrolizumab in patients with advanced renal cell cancer: a non-randomised, open-label, dose-finding, and dose-expansion phase 1b trial[J]. Lancet Oncol, 2018, 19:405-415. doi:  10.1016/S1470-2045(18)30081-0
    [12] Choueiri TK, Larkin JM, Oya M, et al. Preliminary results for avelumab plus axitinib as first-line therapy in patients with advanced clear-cell renal-cell carcinoma (JAVELIN Renal 100): an open-label, dose-finding and dose-expansion, phase 1b trial[J]. Lancet Oncol, 2018, 19:451-460. doi:  10.1016/S1470-2045(18)30107-4
    [13] Lee C, Makker V, Rasco D, et al. A Phase 1b/2 Trial of Lenvatinib Plus Pembrolizumab in Patients With Renal Cell Carcinoma[C]. Ann Oncol, 2017, 28: v295-v329.
    [14] Armstrong AJ, Halabi S, Eisen T, et al. Everolimus versus sunitinib for patients with metastatic non-clear cell renal cell carcinoma (ASPEN): a multicentre, open-label, randomised phase 2 trial[J]. Lancet Oncol, 2016, 17:378-388. doi:  10.1016/S1470-2045(15)00515-X
    [15] Tannir NM, Jonasch E, Albiges L, et al. Everolimus Versus Sunitinib Prospective Evaluation in Metastatic Non-Clear Cell Renal Cell Carcinoma (ESPN): A Randomized Multicenter Phase 2 Trial[J]. Eur Urol, 2016, 69:866-874. doi:  10.1016/j.eururo.2015.10.049
    [16] Cancer Genome Atlas Research Network, Linehan WM, Spellman PT, et al. Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma[J]. N Engl J Med, 2016, 374:135-145. doi:  10.1056/NEJMoa1505917
    [17] Campbell MT, Bilen MA, Duran C, et al. Cabozan-tinib for the treatment of patients with metastatic variant histology renal cell carcinoma (vhRCC): A retrospective study[C]. J Clin Oncol, 2017, 35: abstract 478.
    [18] Choueiri TK, Vaishampayan U, Rosenberg JE, et al. Phase Ⅱ and biomarker study of the dual MET/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma[J]. J Clin Oncol, 2013, 31:181-186.
    [19] Choueiri TK, Plimack E, Arkenau HT, et al. Biomarker-Based Phase Ⅱ Trial of Savolitinib in Patients With Advanced Papillary Renal Cell Cancer[J]. J Clin Oncol, 2017, 35:2993-3001. doi:  10.1200/JCO.2017.72.2967
    • 相关文章
    • 施引文献
  • 资源附件(0)
  • 加载中
WeChat 点击查看大图
计量
  • 文章访问数:  383
  • HTML全文浏览量:  91
  • PDF下载量:  975
  • 被引次数: 0
出版历程
  • 收稿日期:  2018-01-29
  • 刊出日期:  2020-09-18

目录

    /

    返回文章
    返回
    友情链接: 国家卫生健康委员会 北京协和医院 中国医学科学院 学术不端检测系统 国际知识资源总库 中国知网 术语在线 中国全科医学
    地址：北京市东城区帅府园1号 北京协和医院老楼7号楼
    3层302室 《协和医学杂志》编辑部
    电话：010-69154261/4262
    E - mail：medj@pumch.cn
    mjpumch@126.com
    期刊网站版权所有：《协和医学杂志》编辑部
    京ICP备 11002662

    本系统由 北京仁和汇智信息技术有限公司 开发    百度统计

    x 关闭 永久关闭

    【温馨提醒】近日，《协和医学杂志》编辑部接到作者反映，有多名不法人员冒充期刊编辑发送见刊通知，鼓动作者添加微信，从而骗取版面费的行为。特提醒您，本刊与作者联系的方式均为邮件通知或电话，稿件进度通知邮箱为：mjpumch@126.com，编辑部电话为：010-69154261，请提高警惕，谨防上当受骗！如有任何疑问，请致电编辑部核实。谢谢！